GMED - Earnings announcements

AUDUBON, Pa., May 07, 2026 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal technology company, today announced its financial results for the first quarter ended March 31, 2026. First Quarter 2026: Worldwide net sales were $759.9 million, an increase of 27.0%, or an increase of 25.5% on a constant currency basis.Base business, excluding Nevro, net sales were $677.2 million, an increase of 13.2%, or an increase of 11.2% on a constant currency basis.GAAP net income for the quarter was $124.3 million.GAAP diluted earnings per share ("EPS") was $0.90, an increase of 66.6%. Non-GAAP diluted EPS was $1.12, an increase of 64.7%. "We're off to a strong start in 20

AUDUBON, Pa., April 16, 2026 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal technology company, will announce its financial results for the first quarter ended March 31, 2026 after the market close on Thursday, May 7, 2026. A copy of the release will be available on the Globus Medical website at www.investors.globusmedical.com. Following the announcement, Globus Medical will hold a teleconference to discuss its performance with the investment community at 4:30 p.m. Eastern Time. Participants may access the conference call live via webcast on the Investors page of Globus Medical's website at https://www.investors.globusmedical.com/news-events/events-webcast

AUDUBON, Pa., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal technology solutions company, today announced its financial results for the fourth quarter and year ended December 31, 2025. Fourth Quarter 2025: Worldwide net sales were $826.4 million, an increase of 25.7%, or an increase of 24.7% on a constant currency basis.Base business, excluding Nevro, net sales were $726.7 million, an increase of 10.6%, or an increase of 9.4% on a constant currency basis.GAAP net income for the quarter was $140.6 million.GAAP diluted earnings per share ("EPS") was $1.03, an increase of 442.6%. Non-GAAP diluted EPS was $1.28, an increase of 52.1%. Full Year

AUDUBON, Pa., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal solutions company, will announce its financial results for the fourth quarter and full-year ended December 31, 2025 after the market close on Tuesday, February 24, 2026. A copy of the release will be available on the Globus Medical website at www.investors.globusmedical.com. Following the announcement, Globus Medical will hold a teleconference to discuss its performance with the investment community at 4:30 p.m. Eastern Time. Participants may access the conference call live via webcast on the Investors page of Globus Medical's website at https://www.investors.globusmedical.com/news-

AUDUBON, Pa., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal solutions company, today announced its financial results for the quarter ended September 30, 2025. Worldwide net sales were $769.0 million, an increase of 22.9%, or an increase of 22.3% on a constant currency basisBase business, excluding Nevro, net sales were $669.8 million, an increase of 7.0%, or an increase of 6.5% on a constant currency basisGAAP net income for the quarter was $119.0 millionGAAP diluted earnings per share ("EPS") was $0.88 and non-GAAP diluted EPS was $1.18, increasing 134.0% and 42.6%, respectively "We are pleased with the strength of our overall results and

AUDUBON, Pa., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal technology company, will announce its financial results for the third quarter ended September 30, 2025 after the market close on Thursday, November 6, 2025. A copy of the release will be available on the Globus Medical website at www.investors.globusmedical.com. Following the announcement, Globus Medical will hold a teleconference to discuss its performance with the investment community at 4:30 p.m. Eastern Time. Participants may access the conference call live via webcast on the Investors page of Globus Medical's website at https://www.investors.globusmedical.com/news-events/events

AUDUBON, Pa., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal solutions company, today announced its financial results for the quarter ended June 30, 2025. Worldwide net sales were $745.3 million, an increase of 18.4%, or an increase of 17.6% on a constant currency basisGAAP net income for the quarter was $202.8 millionGAAP diluted earnings per share ("EPS") was $1.49 and non-GAAP diluted EPS was $0.86 "Q2 results were led by our US Spine business, growing 5.7%, as reported and 7.4% on a day-adjusted basis. US Spine had sustained momentum during the quarter, posting its highest sequential revenue growth since the second quarter of 2022,"

CHARLOTTE, N.C., July 21, 2025 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona" or "the Company") (NASDAQ:XRAY) today announced that Daniel Scavilla, an established business leader with more than three decades of experience in the medical technology and pharmaceutical industries and a current member of the Board of Directors of Dentsply Sirona (the "Board"), has been appointed President and Chief Executive Officer, effective August 1, 2025. He succeeds Simon Campion, who is leaving the Company on July 31, 2025.  Mr. Scavilla recently served as President and Chief Executive Officer of Globus Medical, where he led the acquisition of NuVasive and oversaw the integration of the two

AUDUBON, Pa., July 17, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal technology company, will announce its financial results for the second quarter ended June 30, 2025 after the market close on Thursday, August 7, 2025. A copy of the release will be available on the Globus Medical website at www.investors.globusmedical.com. Following the announcement, Globus Medical will hold a teleconference to discuss its performance with the investment community at 4:30 p.m. Eastern Time. Participants may access the conference call live via webcast on the Investors page of Globus Medical's website at https://www.investors.globusmedical.com/news-events/events-webca

AUDUBON, Pa., May 08, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal solutions company, today announced its financial results for the quarter ended March 31, 2025. Worldwide net sales were $598.1 million, a decrease of 1.4%, or a decrease of 0.8% on a constant currency basisGAAP net income for the quarter was $75.5 millionGAAP diluted earnings per share ("EPS") was $0.54 and non-GAAP diluted EPS was $0.68 "Our first quarter results were impacted by softer Enabling Technology deal closures, temporary integration related supply chain disruption, and timing of international distributor orders, partially offset by strength in our core US spine busine

AUDUBON, Pa., April 17, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal technology company, will announce its financial results for the first quarter ended March 31, 2025 after the market close on Thursday, May 8, 2025. A copy of the release will be available on the Globus Medical website at www.investors.globusmedical.com. Following the announcement, Globus Medical will hold a teleconference to discuss its performance with the investment community at 4:30 p.m. Eastern Time. Participants may access the conference call live via webcast on the Investors page of Globus Medical's website at https://www.investors.globusmedical.com/news-events/events-webcast

REDWOOD CITY, Calif., March 4, 2025 /PRNewswire/ -- Nevro Corp. (NYSE:NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today reported its fourth-quarter and full-year 2024 financial results. "We are pleased that adjusted EBITDA for the full-year 2024 came in ahead of our revised expectations and that our balance sheet remains strong, reflecting our ongoing focus on working capital management and the benefits from our 2024 restructurings," said Kevin Thornal, Nevro's president and CEO. "Importantly, we look forward to joining forces with Globus Medical to achieve our full potential and working together to free

AUDUBON, Pa., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal technology company, today announced its financial results for the fourth quarter and year ended December 31, 2024. Fourth Quarter 2024: Worldwide net sales were $657.3 million, an increase of 6.6% on an as-reported basis and an increase of 6.9% on a constant currency basisGAAP net income for the quarter was $26.5 millionGAAP diluted earnings per share ("EPS") was $0.19 and non-GAAP diluted EPS was $0.84Non-GAAP adjusted EBITDA was $196.9 million, or 30.0% of net sales Full Year 2024: Worldwide net sales were $2,519.4 million, an increase of 60.6% on an as-reported basis a

AUDUBON, Pa. and REDWOOD CITY, Calif., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Globus Medical (NYSE:GMED), a leading musculoskeletal solutions company, and Nevro Corp. (NYSE:NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced they have entered into a definitive agreement for Globus Medical to acquire all shares of Nevro in an all-cash transaction. Under the terms of the agreement, which was unanimously approved by the boards of directors of both companies, Globus Medical will acquire all shares of Nevro for $5.85 per share. The transaction represents a total equity value of approximately $250 million.

AUDUBON, Pa., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal solutions company, will announce its financial results for the fourth quarter and full-year ended December 31, 2024 after the market close on Thursday, February 20, 2025. A copy of the release will be available on the Globus Medical website at www.investors.globusmedical.com. Following the announcement, Globus Medical will hold a teleconference to discuss its performance with the investment community at 4:30 p.m. Eastern Time. Participants may access the conference call live via webcast on the Investors page of Globus Medical's website at https://www.investors.globusmedical.com/news

AUDUBON, Pa., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal solutions company, today announced its financial results for the quarter ended September 30, 2024. Worldwide net sales were $625.7 million, an increase of 63.1%GAAP net income for the quarter was $51.8 millionGAAP diluted earnings per share ("EPS") was $0.38 and non-GAAP diluted EPS was $0.83Non-GAAP adjusted EBITDA was $193.7 million, or 31.0% of net sales "Our third quarter results reflect the enduring strength of our business. We've continued to deliver on our business objectives to drive sales growth, launch new products, and execute our integration plans, all while delivering

AUDUBON, Pa., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal solutions company, will announce its financial results for the third quarter ended September 30, 2024 after the market close on Tuesday, November 5, 2024. A copy of the release will be available on the Globus Medical website at www.investors.globusmedical.com. Following the announcement, Globus Medical will hold a teleconference to discuss its performance with the investment community at 4:30 p.m. Eastern Time. Participants may access the conference call live via webcast on the Investors page of Globus Medical's website at https://www.investors.globusmedical.com/news-events/events-w

AUDUBON, Pa., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal solutions company, today announced its financial results for the quarter ended June 30, 2024. Worldwide net sales were $629.7 million, an increase of 115.9% or 117.3% on a constant currency basisGAAP net income for the quarter was $31.8 millionGAAP diluted earnings per share ("EPS") was $0.23 and non-GAAP diluted EPS was $0.75Non-GAAP adjusted EBITDA was $190.4 million, or 30.2% of net sales "I'm pleased with the quarterly results, demonstrating our team's strong performance as we continue to execute our long-term growth strategy, deliver on NuVasive integration plans, laun

AUDUBON, Pa., July 16, 2024 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal solutions company, will announce its financial results for the second quarter ended June 30, 2024 after the market close on Tuesday, August 6, 2024. A copy of the release will be available on the Globus Medical website at www.investors.globusmedical.com. Following the announcement, Globus Medical will hold a teleconference to discuss its performance with the investment community at 4:30 p.m. Eastern Time. Participants may access the conference call live via webcast on the Investors page of Globus Medical's website at https://www.investors.globusmedical.com/news-events/events-webcast

AUDUBON, Pa., May 07, 2024 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal solutions company, today announced its financial results for the quarter ended March 31, 2024. Worldwide net sales were $606.7 million, an increase of 119.3%, or 119.8% on a constant currency basisGAAP net loss for the quarter was $7.1 millionGAAP diluted earnings per share ("EPS") was ($0.05) and non-GAAP diluted EPS was $0.72Non-GAAP adjusted EBITDA was $166.6 million, or 27.5% of net sales "Since the NuVasive merger closed in September of last year, we worked aggressively to execute our integration strategy and are making significant progress towards rapidly reaching steady state

AUDUBON, Pa., April 16, 2024 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal solutions company, will announce its financial results for the first quarter ended March 31, 2024 after the market close on Tuesday, May 7, 2024. A copy of the release will be available on the Globus Medical website at www.investors.globusmedical.com. Following the announcement, Globus Medical will hold a teleconference to discuss its performance with the investment community at 4:30 p.m. Eastern Time. Participants may access the conference call live via webcast on the Investors page of Globus Medical's website at https://www.investors.globusmedical.com/news-events/events-webcasts.

AUDUBON, Pa., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal technology company, today announced its financial results for the fourth quarter and year ended December 31, 2023. Fourth Quarter 2023: Worldwide net sales were $616.5 million, an increase of 124.6%, or 123.8% on a constant currency basisGAAP net income for the quarter was $15.0 millionGAAP diluted earnings per share ("EPS") was $0.11 and non-GAAP diluted EPS was $0.60Non-GAAP adjusted EBITDA was $170.0 million, or 27.6% of net sales Full Year 2023: Worldwide net sales were $1,568.5 million, an increase of 53.3% on an actual and constant currency b

AUDUBON, Pa., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal solutions company, will announce its financial results for the fourth quarter and full year ended December 31, 2023 after the market close on Tuesday, February 20, 2024. A copy of the release will be available on the Globus Medical website at www.investors.globusmedical.com. Following the announcement, Globus Medical will hold a teleconference to discuss its performance with the investment community at 4:30 p.m. Eastern Time. Participants may access the conference call live via webcast on the Investors page of Globus Medical's website at https://www.investors.globusmedical.com/news-

AUDUBON, Pa., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal solutions company, today announced its financial results for the quarter ended September 30, 2023. The merger with NuVasive, Inc. was completed on September 1, 2023 and results presented within include NuVasive, Inc. results from that closing date. Worldwide net sales were $383.6 million, an increase of 51.0%.GAAP net income for the quarter was $1.0 millionGAAP diluted earnings per share ("EPS") was $0.01 and non-GAAP diluted EPS was $0.57Non-GAAP adjusted EBITDA was $112.9 million, or 29.4% of net salesStand-alone Globus Medical net sales were $281.2 million, an increase of 10.7%

AUDUBON, Pa., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal solutions company, will announce its financial results for the third quarter ended September 30, 2023 after the market close on Tuesday, November 7, 2023. A copy of the release will be available on the Globus Medical website at www.investors.globusmedical.com. Following the announcement, Globus Medical will hold a teleconference to discuss its performance with the investment community at 4:30 p.m. Eastern Time. Participants may access the conference call live via webcast on the Investors page of Globus Medical's website at https://www.investors.globusmedical.com/news-events/events-w

—Creates leading global musculoskeletal company——Robust portfolio well-positioned for long-term growth and continued innovation— AUDUBON, Pa., Sept. 01, 2023 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal solutions company, today announced it has completed its previously announced merger with NuVasive, Inc. The combined company will provide surgeons and patients with one of the most comprehensive offerings of musculoskeletal procedural solutions and enabling technologies to impact the care continuum. "We're thrilled to begin our journey together to create a leading global musculoskeletal company," said Dan Scavilla, president and chief executive offic

AUDUBON, Pa., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal solutions company, today announced its financial results for the quarter ended June 30, 2023. Worldwide net sales were $291.6 million, an increase of 10.6%GAAP net income for the quarter was $57.7 millionGAAP diluted earnings per share ("EPS") was $0.57 and non-GAAP diluted EPS was $0.63Non-GAAP adjusted EBITDA was $96.1 million, or 33.0% of net sales "Globus achieved a record quarter, delivering our highest quarterly revenue yet of $292 million, an increase of 10.6% over the second quarter of 2022. Non-GAAP EPS was $0.63, an increase of 12.3%" said Dan Scavilla, President

AUDUBON, Pa., July 13, 2023 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal solutions company, will announce its financial results for the second quarter ended June 30, 2023 after the market close on Thursday, August 3, 2023. A copy of the release will be available on the Globus Medical website at www.investors.globusmedical.com. Following the announcement, Globus Medical will hold a teleconference to discuss its performance with the investment community at 4:30 p.m. Eastern Time. Participants may access the conference call live via webcast on the Investors page of Globus Medical's website at https://www.investors.globusmedical.com/news-events/events-webcas

AUDUBON, Pa., May 04, 2023 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal solutions company, today announced its financial results for the quarter ended March 31, 2023. Worldwide net sales were $276.7 million, an increase of 20.0%, or 21.0% on a constant currency basisGAAP net income for the quarter was $49.1 millionGAAP diluted earnings per share ("EPS") was $0.48 and non-GAAP diluted EPS was $0.53Non-GAAP adjusted EBITDA was $85.1 million, or 30.8% of net sales "Globus achieved a record quarter, delivering our highest quarterly revenue yet of $277 million, an increase of 21% over the first quarter of 2022 on a constant currency basis. Non-GAAP EPS was $

AUDUBON, Pa., April 19, 2023 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal solutions company, will announce its financial results for the first quarter ended March 31, 2023 after the market close on Thursday, May 4, 2023. A copy of the release will be available on the Globus Medical website at www.investors.globusmedical.com. Following the announcement, Globus Medical will hold a teleconference to discuss its performance with the investment community at 4:30 p.m. Eastern Time. Participants may access the conference call live via webcast on the Investors page of Globus Medical's website at https://www.investors.globusmedical.com/news-events/events-webcas

AUDUBON, Pa., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal solutions company, today announced its financial results for the fourth quarter and year ended December 31, 2022. Fourth Quarter 2022: Worldwide net sales were $274.5 million, an increase of 9.8%, or 11.7% on a constant currency basisGAAP net income for the quarter was $50.1 millionGAAP diluted earnings per share ("EPS") was $0.49 and non-GAAP diluted EPS was $0.59Non-GAAP adjusted EBITDA was $90.2 million, or 32.8% of net sales Full Year 2022: Worldwide net sales were $1,022.8 million, an increase of 6.8%, or 8.2% on a constant currency basisGAAP net income for the year was $190

Capitalizes on complementary global commercial organizations and accelerates Globus Medical's and NuVasive's globalization strategies to increase customer reach and deepen surgeon relationships Brings together innovative technologies to create comprehensive procedural solutions offering to better support surgeons, healthcare providers and patients Leverages shared commitment to innovation to further both companies' efforts to address the full continuum of care and help solve unmet clinical needs Expands operational excellence capabilities to further serve and enable the combined commercial organizations to better support customers Strong financial profile and value creation opportunity Compa

AUDUBON, Pa., Feb. 02, 2023 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal solutions company, will announce its financial results for the fourth quarter and full year ended December 31, 2022 after the market close on Tuesday, February 21, 2023. A copy of the release will be available on the Globus Medical website at www.investors.globusmedical.com. Following the announcement, Globus Medical will hold a teleconference to discuss its performance with the investment community at 4:30 p.m. Eastern Time. Participants may access the conference call live via webcast on the Investors page of Globus Medical's website at https://www.investors.globusmedical.com/news-

AUDUBON, Pa., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal solutions company, today announced its financial results for the quarter ended September 30, 2022. Worldwide net sales were $254.1 million, an increase of 10.6%, or 12.6% on a constant currency basisGAAP net income for the quarter was $47.4 millionGAAP diluted earnings per share ("EPS") was $0.47 and non-GAAP diluted EPS was $0.50Non-GAAP adjusted EBITDA was $82.8 million, or 32.6% of net sales "Our third quarter sales grew 12.6% on a constant currency basis, as we continue to make market share gains by providing industry leading innovative solutions in spine care," commented Dan S

AUDUBON, Pa., Oct. 19, 2022 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal solutions company, will announce its financial results for the third quarter ended September 30, 2022 after the market close on Tuesday, November 8, 2022. A copy of the release will be available on the Globus Medical website at www.investors.globusmedical.com. Following the announcement, Globus Medical will hold a teleconference to discuss its performance with the investment community at 4:30 p.m. Eastern Time. Participants may access the conference call live via webcast on the Investors page of Globus Medical's website at https://www.investors.globusmedical.com/news-events/events-w

AUDUBON, Pa., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal solutions company, today announced its financial results for the quarter ended June 30, 2022. Worldwide net sales were $263.6 million, an increase of 5.0% as reported, and an increase of 6.5% on a constant currency basis, compared to the second quarter of 2021GAAP net income for the quarter was $54.6 millionGAAP diluted earnings per share ("EPS") was $0.53 and non-GAAP diluted EPS was $0.56Non-GAAP adjusted EBITDA was $91.9 million, or 34.9% of net sales "Our second quarter record sales grew 6.5% on a constant currency basis and accelerated from last quarter as we continue to make

AUDUBON, Pa., July 18, 2022 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal solutions company, will announce its financial results for the second quarter ended June 30, 2022 after the market close on Thursday, August 4, 2022. A copy of the release will be available on the Globus Medical website at www.investors.globusmedical.com. Following the announcement, Globus Medical will hold a teleconference to discuss its performance with the investment community at 4:30 p.m. Eastern Time. Participants may access the conference call live via webcast on the Investors page of Globus Medical's website at https://www.investors.globusmedical.com/news-events/events-webcas

AUDUBON, Pa., May 10, 2022 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal solutions company, today announced its financial results for the first quarter ended March 31, 2022. Worldwide net sales were $230.5 million, an increase of 1.4% as compared to the first quarter of 2021GAAP net income for the quarter was $38.1 millionGAAP diluted earnings per share ("EPS") was $0.37 and non-GAAP diluted EPS was $0.42Non-GAAP adjusted EBITDA was $74.3 million, or 32.2% of net sales "Our first quarter results delivered top line growth in a period that faced headwinds of a difficult prior year comparative and COVID-19 deferra

AUDUBON, Pa., April 21, 2022 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal solutions company, will announce its financial results for the first quarter ended March 31, 2022 after the market close on Tuesday, May 10, 2022. A copy of the release will be available on the Globus Medical website at www.globusmedical.com/investors. Following the announcement, Globus Medical will hold a teleconference to discuss its performance with the investment community at 4:30 p.m. Eastern Time. Globus invites all interested parties to join the call by dialing: 1-866-374-5140; passcode 1585-8936 For interested parties who do not wish to ask questions, the teleconference w

AUDUBON, Pa., April 21, 2022 (GLOBE NEWSWIRE) --  Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal solutions company, today announced the resignation of President and Chief Executive Officer, Dave Demski, after nearly 20 years with the company, with the last four and a half years as its CEO. The Board of Directors has named Daniel T. Scavilla as the Company's President and Chief Executive Officer, effective immediately. Globus Medical Founder and Executive Chairman, David C. Paul stated, "Dave has been a great partner to me and a truly integral part of Globus, from its humble beginnings in 2003 to a global, publicly-traded medical device company with annual revenue approaching

AUDUBON, Pa., Feb. 17, 2022 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal solutions company, today announced its financial results for the fourth quarter and year ended December 31, 2021. Fourth Quarter 2021: Worldwide net sales were $250.0 million, an increase of 7.1% as compared to the fourth quarter of 2020GAAP net income for the quarter was $15.1 millionGAAP diluted earnings per share ("EPS") was $0.14 and non-GAAP diluted EPS was $0.49Non-GAAP adjusted EBITDA was $85.2 million, or 34.1% of net sales Full Year 2021:

AUDUBON, Pa., Jan. 27, 2022 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal solutions company, will announce its financial results for the fourth quarter and full year ended December 31, 2021 after the market close on Thursday, February 17, 2022. A copy of the release will be available on the Globus Medical website at www.globusmedical.com/investors. Following the announcement, Globus Medical will hold a teleconference to discuss its performance with the investment community at 4:30 p.m. Eastern Time. Globus invites all interested parties to join the call by dialing: 1-877-313-2501 United States Participants1-929-517-0907 International Participants There

AUDUBON, Pa., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal solutions company, today announced its financial results for the quarter ended September 30, 2021. Worldwide net sales were $229.7 million, an increase of 6.3% as compared to the third quarter of 2020GAAP net income for the quarter was $47.2 million, or 20.6% of net sales, which is an increase of 6.8% as compared to the third quarter of 2020GAAP diluted earnings per share ("EPS") was $0.45 and non-GAAP diluted EPS was $0.50Non-GAAP adjusted EBITDA was $78.3 million, or 34.1% of net sales "Revenue in the third quarter was $230

AUDUBON, Pa., Oct. 14, 2021 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal solutions company, will announce its financial results for the third quarter ended September 30, 2021 after the market close on Thursday, November 4, 2021. A copy of the release will be available on the Globus Medical website at www.globusmedical.com/investors. Following the announcement, Globus Medical will hold a teleconference to discuss its performance with the investment community at 4:30 p.m. Eastern Time. Globus invites all interested parties to join the call by dialing:  1-877-313-2501 United States Participants1-929-517-0907 International Participants There is no passcode

AUDUBON, Pa., Aug. 04, 2021 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal solutions company, today announced its financial results for the quarter ended June 30, 2021. Worldwide net sales were $251.0 million, an increase of 68.6% as compared to the second quarter of 2020 GAAP net income for the quarter was $41.5 million, or 16.6% of net sales, which is an increase of 299.4% as compared to the second quarter of 2020 GAAP diluted earnings per share ("EPS") was $0.40 and non-GAAP diluted EPS was $0.56 Non-GAAP adjusted EBITDA was $87.8M, or 35.0% of net sales "Revenue in the second quarter was a record $251 million, an increase of 69%

AUDUBON, Pa., May 04, 2021 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal solutions company, today announced its financial results for the quarter ended March 31, 2021. Worldwide net sales were $227.3 million, an increase of 19.3% as compared to the first quarter of 2020GAAP net income for the quarter was $45.3 million, or 19.9% of net sales, which is an increase of 74.7% as compared to the first quarter of 2020GAAP diluted earnings per share ("EPS") was $0.44 and non-GAAP diluted EPS was $0.49Non-GAAP adjusted EBITDA was $81.0 million, or 35.2% of net sales "We got off to a great start in the first quarter, continuing the momentum we established in 2020,

AUDUBON, Pa., Feb. 17, 2021 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced its financial results for the fourth quarter and year ended December 31, 2020. Fourth Quarter 2020: Worldwide net sales were $233.4 million, an increase of 10.3% as compared to the fourth quarter of 2019GAAP net income for the quarter was $53.0 million, or 22.7% of net salesGAAP diluted earnings per share (“EPS”) was $0.52 and non-GAAP diluted EPS was $0.58Non-GAAP adjusted EBITDA was 36.2% of net sales Full Year 2020: Worldwide net sales were $789.0 million, an increase of 0.5% as compared to the full year of 2019GAAP net income for the year w